Literature DB >> 10796826

SSRIs versus other antidepressants for depressive disorder.

J R Geddes1, N Freemantle, J Mason, M P Eccles, J Boynton.   

Abstract

OBJECTIVES: To examine the relative efficacy of selective serotonin reuptake inhibitors (SSRIs) compared to other antidepressants. SEARCH STRATEGY: The search strategy included a search of (a) Electronic bibliographic databases (MEDLINE, EMBASE); (b) reference lists of related reviews (c) reference lists of all located studies (d) contact with the manufacturer and (e) the Cochrane Group register of controlled trials SELECTION CRITERIA: Randomised controlled trials comparing selective serotonin reuptake inhibitors with other kinds of antidepressants in the treatment of patients with depressive disorders. The outcome measures assessed included measures of the severity of depression. DATA COLLECTION AND ANALYSIS: Data were collected from each study the main outcome measurefrom each study. These included: mean Hamilton depression rating scale, mean Montgomery & Asberg depression rating scale, Clinical Global Impression rating scale. An analysis of standardised mean difference of these scales was performed using Review Manager 3. 1 software. The presence of heterogeneity of treatment effect was assessed MAIN
RESULTS: Ninety-eight trials contributed data to the analysis of the relative efficacy of SSRIs and related drugs with comparator antidepressants (Figure 3 & Appendix 3). Analysis of efficacy was based upon 5044 patients treated with an SSRI or related drug, and 4510 treated with an alternative antidepressant. The standardised effect size for SSRIs and related drugs together versus alternative antidepressants using a fixed effects model was 0. 035 (95% CI -0.006 to 0.076; Q = 149.25, df = 97, p < 0.001). REVIEWER'S
CONCLUSIONS: There are no clinically significant differences in effectiveness between selective serotonin reuptake inhibitors and tricyclic antidepressants. Treatment decisions need to be based on considerations of relative patient acceptability, toxicity and cost.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10796826     DOI: 10.1002/14651858.CD001851

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  21 in total

1.  Most patients depressed by cancer do not need drugs.

Authors:  Ulrich S Schuler
Journal:  BMJ       Date:  2002-11-09

2.  Selective serotonin reuptake inhibitors.

Authors:  John R Geddes; Andrea Cipriani
Journal:  BMJ       Date:  2004-10-09

Review 3.  Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials.

Authors:  Dean Fergusson; Steve Doucette; Kathleen Cranley Glass; Stan Shapiro; David Healy; Paul Hebert; Brian Hutton
Journal:  BMJ       Date:  2005-02-19

4.  Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations.

Authors:  Hans-Jürgen Möller; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02       Impact factor: 5.270

5.  Paroxetine versus other anti-depressive agents for depression.

Authors:  Andrea Cipriani; Toshi A Furukawa; Antonio Veronese; Norio Watanabe; Rachel Churchill; Hugh McGuire; Corrado Barbui
Journal:  Cochrane Database Syst Rev       Date:  2007

6.  Venlafaxine versus other anti-depressive agents for depression.

Authors:  Andrea Cipriani; Alessandra Signoretti; Toshi A Furukawa; Rachel Churchill; Silva Tomelleri; Ichiro M Omori; Hugh McGuire; Corrado Barbui
Journal:  Cochrane Database Syst Rev       Date:  2007

Review 7.  Lithium versus antidepressants in the long-term treatment of unipolar affective disorder.

Authors:  A Cipriani; K Smith; S Burgess; S Carney; G Goodwin; J Geddes
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 8.  Solving the antidepressant efficacy question: effect sizes in major depressive disorder.

Authors:  Paul A Vöhringer; S Nassir Ghaemi
Journal:  Clin Ther       Date:  2011-12-02       Impact factor: 3.393

9.  Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study.

Authors:  Elena Di Nasso; Alberto Chiesa; Alessandro Serretti; Diana De Ronchi; Claudio Mencacci
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 10.  The role of the serotonergic system at the interface of aggression and suicide.

Authors:  M Bortolato; N Pivac; D Muck Seler; M Nikolac Perkovic; M Pessia; G Di Giovanni
Journal:  Neuroscience       Date:  2013-01-16       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.